Clinical trial
A Single-Center, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of QLS4131 in Combination With Isa-V-CHOP in Previously Untreated, HIV-Negative Patients With Plasmablastic Lymphoma (PBL)
NCT07921615 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, Phase 2, 10 participants (estimated). Lead sponsor Institute of Hematology & Blood Diseases Hospital, China. Primary measure: Complete response rate (CRR).
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Center, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of QLS4131 in Combination With Isa-V-CHOP in Previously Untreated, HIV-Negative Patients With Plasmablastic Lymphoma (PBL)
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- December 30, 2028
- Enrollment
- 10 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| TsAb-treatment group | Experimental | QLS4131 combined with Isa-V-CHOP |
Show registry wordingEligible patients who meet the inclusion/exclusion criteria will receive QLS4131 combined with the Isa-V-CHOP regimen after enrollment, with each cycle lasting 21 days; efficacy will be assessed after Cycles 2 and 4 and after completion of Cycle 6. After completing 6 cycles and the primary endpoint assessment, patients with advanced-stage disease (Ann Arbor stage III-IV) may receive autologous hematopoietic stem cell transplantation or QLS4131 monotherapy maintenance for 6 cycles; patients with limited-stage disease (stage I-II) may be considered for local radiotherapy. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Complete response rate (CRR) | 6 months |
Lead sponsor's other trials
Institute of Hematology & Blood Diseases Hospital, China, most recent start first.
+407 more trials See the organization page
Similar trials
Same condition (Plasmablastic Lymphoma) and phase, most recent start first.